We are pleased to announce that Bioengineering AG (hereinafter referred to as "Bioengineering") has officially joined the Morimatsu Group. This integration represents a significant milestone in Morimatsu LifeSciences global strategy and substantially enhances Morimatsu’s capabilities in the biopharmaceutical and synthetic biology sectors.

By strengthening technological advantages and expanding market coverage in core equipment such as bioreactors and fermentation system, this acquisition will accelerate Morimatsu’s penetration and competitiveness in global high-end markets. Furthermore, Bioengineering will synergize with other brands within the Group to extend Morimatsu’s upstream bioprocessing value chain, offering customers a broader portfolio of solutions and delivering enhanced value to downstream industries.

With the joining of Bioengineering, the Morimatsu Group now boasts two renowned European brands. Among them, Pharmadule Morimatsu AB (Sweden), an industry pioneer, has specialized in the R&D, design, fabricates and delivery of modular facilities for the pharmaceutical and FMCG industries. The acquisition of Bioengineering will further strengthen Morimatsu’s competitiveness in the high-end bioprocessing market, enhancing its technological leadership and market presence in bioreactors and fermentation systems, while upgrade the “global R &D and production diversification” strategy.

In the future, Morimatsu will significantly improve its responsiveness, local service capabilities, and technical support efficiency in Europe and other key international markets. The Group’s global supply chain synergies will become increasingly prominent, ultimately strengthening the multi-brand portfolio and building a more resilient and diversified competitive advantage worldwide.

As an international enterprise, the Morimatsu Group has established cross-industry collaborations with numerous Fortune 500 companies, including 80% of the world’s top 20 pharmaceutical companies, as well as leading regional and sector-specific clients. Bioengineering is a globally recognized, R&D-driven manufacturer renowned for pioneering high-end bioreactor and cultivation systems. With over half a century of technological expertise and proven market performance, it stands as an industry benchmark, with products and services highly regarded across global high-end markets.

The collaboration between the two entities will generate a cascading synergistic effect in the field of bioreactors and cultivation systems. Morimatsu’s advanced, efficient, and large-scale production bases will integrate deeply with Bioengineering’s technological strengths to offer global customers more flexible and customized solutions. Together, they will leverage a broader solution portfolio, a more premium value proposition, and enhanced service systems to realize synergies and explore new market opportunities.

Bioengineering’s accumulated expertise will be effectively merged with Morimatsu’s global technical teams, fostering continuous innovation through collaborative initiatives. The two brands will jointly sustain industry leadership and achieve a mutually reinforcing development model, enabling shared growth in the global high-end bioprocessing industry.

About Bioengineering AG

Bioengineering AG is a leading European company specializing in the development, design, and manufacturing of advanced bioreactor systems. With over 50 years of experience, the company has built a strong worldwide reputation for technical excellence. Its global client base benefits from a comprehensive technology portfolio that spans the entire spectrum of bioreaction, and cultivation needs—from laboratory R&D and pilot-scale studies to industrial-scale production. Bioengineering AG provides end-to-end bioreactor and cultivation systems that deliver reliable support for innovation and commercialization in biotechnology.

About Morimatsu LifeSciences

Morimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK). It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai Morisora Technology Co., Ltd., Pharmadule Morimatsu AB, and its affiliated companies.

Morimatsu LifeSciences is dedicated in providing core equipment, process systems, and smart modular facility solutions, and services for the pharmaceutical, biopharmaceutical, medical aesthetics, and fast-moving consumer goods (FMCG) sectors including (cosmetics, food, and health supplements), as well as data centers.

Our team comprises highly experienced professionals with deep expertise in process R&D, engineering design, advanced manufacturing, compliance and validation consulting, production execution, and intelligent operations. With broad experience across diverse industries, we fully understand the unique characteristics and process requirements of various products. This enables us to deliver tailored, end-to-end process solutions from the conceptual design stage, precisely aligned with client’s specific needs.

Morimatsu LifeSciences has established a strong global presence, supported by advanced R&D centers, design hubs, and state-of-the-art manufacturing facilities worldwide. Our well-established service network spans Europe,USA,Asia-Pacific, and emerging markets. We have successfully delivered outstanding, customized solutions to clients in over 40 countries and regions, gaining extensive experience in international project execution.

As a multinational enterprise with core strengths in process technology, modular facility construction, and intelligent manufacturing, Morimatsu LifeSciences is dedicated to meeting the evolving equipment and system needs of our key industries. Through continuous innovation and technological advancement, we are steadily expanding our global footprint, driving our international strategy forward, and delivering Morimatsu’s expertise, reliability, and innovation to the global life sciences and related sectors.